Compare iShares MSCI Indonesia ETF (EIDO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 24.6× iShares MSCI Indonesia ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Twist Bioscience Corp for 27 Days on average.
| EIDO | TWST | |
|---|---|---|
Market Cap | $409.22M | $10.08B |
Volume | 879,527 | 4,229,037 |
52-Week High | $19.22 | $205.00 |
52-Week Low | $10.80 | $25.45 |
Typical Hold Time | 76 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.67, down 1.6% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF's financial ratios are not disclosed in available data, but recent news highlights its exposure to Indonesian equities and a challenging technical downtrend. Trading volume remains active, though recent sessions show a decline from average levels.
The outlook for EIDO is cautious due to weak price action and sector concentration risks, with limited upside from low earnings growth. Key risks include dependence on financials and commodity markets, while potential opportunities may arise from seasonal trends or valuation rebounds if investor sentiment improves.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
